MedEdge Series

100

MOLECULAR TUMOR BOARD CASES

Learning Precision Oncology, One Case at a Time

CASE – 4

Dual PI3K and HRD Signals in Heavily Pretreated Metastatic HR+/HER2– Breast Cancer

Feedback & Suggestion : +91 63746 46112 dr.arunseshachalamtalks@gmail.com

www.youtube.com/@MedEdgeSeries

CHAPTER 4

Dual PI3K and HRD Signals in Heavily Pretreated Metastatic HR+/HER2- Breast Cancer

Case Overview

Table 1: At-a-Glance Case Summary

Domain	Key Information
Case Title	Navigating Dual PI3K and HRD Signals in Heavily Pretreated Metastatic HR+/HER2– Breast Cancer
Patient Profile	60-year-old postmenopausal woman
Performance Status	ECOG 2
Cancer Type	Metastatic ER-positive, PR-positive, HER2-negative invasive ductal carcinoma
Disease Sites	Visceral metastases (progressive disease on imaging)
Prior Therapies	Anastrozole + Palbociclib + Zoledronic acid → Fluvastatin + Palbociclib + Denosumab → Paclitaxel + Carboplatin (rapid progression ~4 months)
Key Molecular Biomarkers	PIK3CA p.E545K (VAF 37%); BRCA2 p. R2318Ter (VAF 5%); TP53 p. Q192Ter (VAF 32%); TMB 9.55 muts/Mb; MSS; PD-L1 negative; PARP1 amplification
Dominant Molecular Features	High-VAF PIK3CA activating mutation (helical domain, clonally dominant); Low-VAF BRCA2 truncating variant (sub clonal); TP53 loss; PARP1 copy gain
Pathway Convergence	PI3K/AKT/mTOR pathway activation (dominant driver) + Sub clonal DNA repair deficiency (BRCA2) + Cell cycle dysregulation (TP53) + DDR modifier (PARP1 amp)
Central Clinical Dilemma	Competing molecular signals: Which pathway to prioritize—PI3K inhibition versus PARP inhibition—in context of low-VAF BRCA2, platinum-refractory phenotype, and high-VAF PIK3CA mutation
MTB Focus	VAF-based clonal architecture analysis; platinum response as functional HRD biomarker; evidence hierarchy for pathway-targeted therapy selection; Indian resource context
Primary Recommendation	Capivasertib 400 mg BID (4 days on/3 days off) + Fluvastatin 500 mg IM; targeting dominant PI3K/AKT pathway. Defer PARP inhibitor; consider germline testing and HRD reassessment at progression

A 60-year-old postmenopausal woman with preserved functional capacity (ECOG performance status 2) and comorbid type 2 diabetes mellitus presented with de novo metastatic hormone receptor-positive, HER2-negative invasive ductal carcinoma of the breast diagnosed in October 2022. Her disease course was characterized by sequential acquisition of endocrine resistance across multiple therapeutic platforms, culminating in visceral crisis requiring platinum-based chemotherapy intervention.

Initial systemic management followed contemporary first-line guidelines: anastrozole with palbociclib (CDK4/6 inhibitor) plus bone-directed therapy with zoledronic acid, reflecting standard-of-care endocrine backbone for hormone-dependent metastatic breast cancer. Disease progression on CDK4/6 inhibition prompted transition to second-line therapy with palbociclib continuation, fulvestrant (selective estrogen receptor degrader), and denosumab —representing sequential hormonal manipulation within the CDK4/6 platform before chemotherapy exposure.

Despite two lines of CDK4/6-inclusive endocrine therapy extending over approximately 24 months, the patient developed symptomatic visceral progression, necessitating escalation to taxane-platinum chemotherapy (paclitaxel with carboplatin). This regimen produced initial disease control but was complicated by rapid symptomatic relapse within 4 months, indicating chemotherapy-refractory biology despite initial platinum sensitivity.

MOLECULAR LANDSCAPE

Comprehensive next-generation sequencing was performed using a 352-gene solid tumor panel (TARGT Focus, 4baseCare) from formal-in-fixed paraffin-embedded (FFPE) tissue obtained at metastatic biopsy (breast primary site, July 2024). Tumor cellularity was suboptimal (30–32%), with mean sequencing coverage exceeding 350×. The genomic profile revealed convergence of PI3K/AKT/mTOR pathway activation, DNA damage response pathway perturbation, and cell cycle control disruption, creating therapeutic complexity in pathway prioritization.

FIGURE 1: Molecular Hierarchy Framework (Conceptual Diagram)



MOLECULAR RESULTS (ABERRATIONS ONLY; CONSOLIDATED)
BIOMARKER STATUS

- Microsatellite status: MSS (microsatellite stable).
- Tumor mutational burden (TMB): 9.55 mutations/megabase (intermediate; below tissue-agnostic ICI threshold).
- PD-L1 expression (SP142 assay): No expression detected.
- HRD score: Not reported (genomic scar-based HRD assessment not performed).

VARIANT-LEVEL SUMMARY (KEY ABERRATIONS)

Gene	Alteration	VAF (%)	Tier/Significance	Pathway
PIK3CA	p. Glu545Lys (c.1633G>A)	37	Tier I (FDA-recognized)	PI3K/AKT/mTOR
BRCA2	p. Arg2318Ter (c.6952C>T)	5	Tier I (FDA-recognized)	HR DNA Repair
TP53	p. Gln192Ter (c.574C>T)	32	Tier II	Cell Cycle Control
SDHB	p. Gly96Ser (c.286G>A)	32	VUS	TCA Cycle
PARP1	Amplification (CN gain 7)	N/A	Tier III	DNA Repair (modifier)

PATHWAY CONVERGENCE (GENOME-TO-BIOLOGY MAP)

- PI3K/AKT/mTOR axis activation: PIK3CA hotspot mutation (helical domain) at high allelic fraction, conferring ligand-independent pathway activation and established endocrine resistance mechanism in HR+ breast cancer (1,2).
- DNA damage response (DDR) vulnerability: Pathogenic BRCA2 nonsense mutation at low allelic fraction, representing partial loss of homologous recombination capacity. Clinical phenotype (rapid platinum relapse) argues against functional HRD dominance despite genomic presence (3,4).
- Cell cycle dysregulation: TP53 loss-of-function (nonsense mutation, high VAF), removing critical G1/S checkpoint control and apoptotic surveillance, characteristic of aggressive luminal biology (5,6).
- Metabolic/TCA cycle perturbation: SDHB missense variant of uncertain significance; clinical relevance unclear in breast cancer context.
- DDR modifier: PARP1 amplification may reflect compensatory DNA repair pathway activation or resistance adaptation to replication stress; association with CDK4/6 inhibitor resistance documented in preclinical models (7,8).

TEACHING POINT – MOLECULAR PROFILING

Variant allelic fraction (VAF) and clonal architecture: High-VAF alterations (PIK3CA 37%, TP53 32%) represent dominant clonal drivers present in the founding tumor population. Low-VAF alterations (BRCA2 5%) may reflect sub-clonal events, late-acquired mutations, or technical detection at the limit of assay sensitivity. In metastatic disease, dominant clonal drivers typically predict therapeutic response more reliably than low fraction sub clonal alterations. Platinum response phenotype provides critical functional validation: lack of durable platinum benefit despite BRCA2 alteration suggests the mutation is either sub clonal (not dominant), functionally compensated, or represents a variant with incomplete loss of homologous recombination. This case exemplifies the principle that genomic presence does not equal biologic dominance.

CLINICAL QUESTIONS POSED TO THE MTB

- Pathway hierarchy and actionability: In a tumor harboring both PIK3CA mutation (high VAF) and BRCA2 alteration (low VAF), which molecular alteration represents the dominant therapeutic target, and how should rapid platinum-refractory phenotype inform this interpretation?
- PARP inhibitor indication in somatic BRCA2 mutations: Does the pathogenic BRCA2 truncating variant justify PARP inhibitor therapy in HR-positive metastatic breast cancer, particularly given the low allelic fraction (5%), absence of germline confirmation, and documented platinum resistance?
- PI3K/AKT pathway targeting strategy: Should PI3K/AKT axis inhibition be prioritized based on the high-VAF PIK3CA activating mutation and established endocrine resistance, and which agent (alpelisib, capivasertib, everolimus) is most appropriate in the Indian resource context?
- Role of platinum response as HRD surrogate: Can rapid platinum relapses be interpreted as functional evidence against meaningful homologous recombination deficiency despite genomic BRCA2 alteration, and does this clinical phenotype override molecular findings?
- Impact of PARP1 amplification: How should PARP1 copy number gain modify therapeutic decision-making—does it represent a resistance mechanism to PARP inhibition, a compensatory DDR pathway, or a neutral passenger event?
- Sequencing depth and tumor purity considerations: Given modest tumor cellularity (30-32%) and sequencing coverage (~350×), should repeat molecular profiling from alternative tissue (e.g., recent metastatic biopsy) or liquid biopsy be considered to resolve low-VAF findings?
- Germline versus somatic BRCA2 status: Does the low VAF BRCA2 truncating variant warrant germline testing to distinguish inherited predisposition from acquired somatic mutation, and would germline status alter therapeutic recommendations?

MTB DISCUSSION: CLINICAL CONTEXT AND DISEASE TRAJECTORY

TREATMENT HISTORY ANALYSIS AND PATTERN RECOGNITION

The MTB devoted significant discussion to deconstructing the patient's treatment sequence, recognizing that therapeutic response patterns provide functional validation of molecular dependencies that genomic data alone cannot establish.

Sequential endocrine therapy exhaustion across CDK4/6 platforms (24+ months combined): The patient received two distinct CDK4/6 inhibitor-based endocrine regimens (palbociclib + anastrozole, then palbociclib + fulvestrant), achieving extended disease control characteristic of CDK4/6-sensitive luminal biology. However, ultimate progression indicated acquisition of endocrine resistance mechanisms, necessitating chemotherapy escalation. This pattern suggested intact estrogen receptor signaling initially, with gradual pathway rewiring rather than de novo resistance.

The PALOMA-2 trial established palbociclib plus letrozole as first-line standard of care in HR+/HER2- advanced breast cancer (median PFS 24.8 vs 14.5 months), while PALOMA-3 demonstrated benefit of palbociclib plus fulvestrant after endocrine progression (median PFS 9.5 vs 4.6 months) (9,10). This patient's disease trajectory through both platforms indicated progressive endocrine resistance beyond CDK4/6 inhibition alone.

Platinum-based chemotherapy: initial response followed by rapid relapse: Administration of taxane-platinum combination (paclitaxel + carboplatin) produced initial disease stabilization but was followed by symptomatic progression within approximately 4 months. The MTB emphasized that this clinical phenotype—transient platinum response without durable benefit—argues strongly against functional homologous recombination deficiency as a dominant driver, despite genomic BRCA2 alteration. In BRCA-deficient tumors with profound HRD, platinum responses typically extend beyond 6–9 months when present, and platinum-refractory phenotype is uncommon in first-line platinum exposure. The TNT trial comparing carboplatin versus docetaxel in metastatic triple-negative breast cancer demonstrated superior response rates for carboplatin in germline BRCA1/2 carriers (68% vs 33%, p=0.03), with median PFS of 6.8 months—substantially longer than this patient's 4-month interval (11). Similarly, pooled analyses of platinum therapy in BRCA-mutated breast cancer show objective response rates of 54-82% with median PFS of 7-9 months when HRD is functionally dominant (12,13).

KEY FEATURES DEFINING ATYPICAL LUMINAL BIOLOGY:

- De Novo metastatic presentation: Diagnosis with synchronous distant disease rather than progression from early-stage breast cancer, indicating intrinsically aggressive phenotype at baseline rather than acquired metastatic competence over time. De Novo stage IV breast cancer comprises approximately 6-10% of new breast cancer diagnoses and is associated with distinct molecular features including higher rates of genomic instability (14).
- High-grade histology with ER+/PR+/HER2- profile: Grade III invasive ductal carcinoma with preserved hormone receptor expression suggests luminal-basal hybrid characteristics, where proliferative index exceeds typical luminal A biology despite maintained ER positivity.
- Dual-pathway endocrine resistance: Sequential progression through two CDK4/6 inhibitor platforms indicates bypass signaling mechanisms. PIK3CA mutations occur in approximately 40% of HR+ breast cancers and provide biologic explanation for ER-independent growth via PI3K/AKT/mTOR activation, establishing this as one of the most common endocrine resistance mechanisms (1,2).
- TP53 loss co-occurring with PIK3CA activation: TP53 inactivation (32% VAF) removes critical apoptotic checkpoint control, synergizing with PI3K pathway activation to create aggressive, therapy-resistant phenotype. TP53 mutations in HR+ breast cancer occur in approximately 20-30% of cases and correlate with worse prognosis, chemotherapy resistance, reduced endocrine responsiveness, and increased risk of progression to metastatic disease (5,6).
- Rapid chemotherapy relapse phenotype: Short-lived response to platinum-based therapy despite initial sensitivity, characteristic of adaptable, genomically unstable disease with multiple resistance mechanisms.

THE MTB CONSENSUS INTERPRETATION:

This tumor represents endocrine-resistant, PI3K-activated, TP53-deficient luminal breast cancer with genomic instability and rapid progression kinetics, where hormone receptor expression persists but no longer defines therapeutic vulnerability.

TEACHING POINT - CLINICAL-GENOMIC INTEGRATION

Aggressive behavior in ER-positive breast cancer should prompt reassessment of lineage biology. Early endocrine resistance, rapid relapse, and high-grade disease often reflect luminal-basal hybridization, reframing expectations from standard endocrine sequencing. Treatment history analysis is as important as molecular profiling—response patterns reveal functional pathway dependencies that static genomic snapshots cannot capture.

Figure 2: Molecular Pathway Integration in Competing Signal Context (Flow Diagram)



MOLECULAR PATHWAY INTERPRETATION (FROM MTB TRANSCRIPT)

1) PIK3CA MUTATION: DOMINANT CLONAL DRIVER OF ENDOCRINE RESISTANCE

The PIK3CA p. Glu545Lys mutation, detected at 37% variant allelic fraction, represents a canonical hotspot alteration within the helical domain of the p110α catalytic subunit. This high-VAF alteration indicates clonal dominance—the mutation is present in most tumor cells and represents a founding driver event rather than a late-acquired sub clonal change (1,2).

MOLECULAR MECHANISMS OF PIK3CA-DRIVEN RESISTANCE

PIK3CA p.E545K functions through multiple interconnected mechanisms that drive endocrine therapy resistance (1,2,15,16):

- Ligand-independent pathway activation: The E545K mutation disrupts normal regulatory interactions between the catalytic (p110α) and regulatory (p85) subunits of PI3K, resulting in constitutive kinase activity independent of upstream growth factor receptor signaling. This creates ER-independent proliferative drive that bypasses estrogen signaling blockade.
- Enhanced AKT phosphorylation and downstream signaling: Constitutive PI3K activity drives sustained AKT activation, which in turn phosphorylates and inactivates multiple downstream targets including FOXO transcription factors, TSC2, and pro-apoptotic proteins, creating a survival-promoting cellular state resistant to endocrine-induced growth arrest.
- Transcriptional reprogramming away from ER dependency: PI3K/AKT signaling alters the transcriptional landscape by modulating ER coactivator/corepressor interactions and inducing expression of ER-independent growth programs.
- Crosstalk with CDK4/6 pathway: PI3K/AKT activation can promote cyclin D1 expression and nuclear localization, providing mechanistic rationale for resistance to CDK4/6 inhibitors despite maintained ER positivity.

2) TP53 P.Q192*: THE ARCHITECT OF GERO CONVERSION AND CDK4/6 INHIBITORS RESISTANCE

TP53 p. Gln192Ter is a truncating loss-of-function variant that abolishes p53's transcriptional control over cell-cycle arrest, apoptosis, and senescence programs. In HR+ breast cancer treated with CDK4/6 inhibitors, durable benefit depends not only on initial RB-mediated G1 arrest but on consolidation of that arrest into a stable, senescence-like state ("Gero conversion"). Experimental models show that p53 loss permits a CDK2-high activation state that maintains p130 hyperphosphorylation, thereby preventing proper DREAM (DP, RB-like, E2F, and MuvB) complex assembly. Without DREAM-mediated repression of E2F target genes, cells re-enter S phase despite ongoing CDK4/6 blockade—constituting a mechanistic basis for resistance. Recent translational studies in human breast cancer systems directly link TP53 deficiency to CDK2-driven escape from CDK4/6 inhibitors and demonstrate that restoring CDK2 suppression re-establishes durable arrest, underscoring CDK2 as the critical bypass node.

Clinically, TP53 mutations are associated with inferior durability of CDK4/6 inhibitor therapy in HR+/HER2− disease across multiple cohorts, supporting a prognostic impact consistent with this biology. Together, these data position TP53 loss as a facilitator of CDK4/6 failure through impaired Gero conversion and CDK2-mediated DREAM disruption, explaining why initial responses may occur but are less likely to be sustained. (31-34)

3) BRCA2 P. ARG2318TER: LOW-VAF ALTERATION WITH UNCERTAIN FUNCTIONAL DOMINANCE

The BRCA2 p. Arg2318Ter nonsense mutation, detected at 5% variant allelic fraction, represents a pathogenic truncating alteration that would be expected to abolish homologous recombination function if present in both alleles and dominant within the tumor cell population. However, multiple lines of evidence from this case suggest that BRCA2 loss is not the dominant driver of therapeutic vulnerability (3,4,17):

- Low allelic fraction (5%): Indicates the mutation is present in only a small subset of tumor cells, suggesting either (a) a sub clonal event acquired late in tumor evolution, (b) incomplete clonal expansion of BRCA2-mutant cells, or (c) technical detection near assay sensitivity limit.
- Rapid platinum relapse phenotype: The patient achieved only ~4 months of progression-free interval after platinum-based chemotherapy, inconsistent with profound homologous recombination deficiency. BRCA1/2-deficient tumors typically demonstrate dramatic and durable platinum sensitivity (often 9–15 months PFS) due to synthetic lethality between platinum-induced DNA crosslinks and impaired HR repair (11-13).
- Absence of genomic HRD signature assessment: The NGS report did not include genomic scar-based HRD scoring. While negative HRD score does not exclude all DNA repair defects, the absence of documented HRD alongside low-VAF BRCA2 mutation and platinum-refractory phenotype collectively argues against functional HRD dominance.
- PARP1 amplification as potential compensatory mechanism: Copy number gain of PARP1 may represent a compensatory upregulation of alternative DNA repair pathways, potentially mitigating BRCA2 loss-of-function effects and conferring resistance to PARP inhibition (7,8).

EVIDENCE REVIEW

1) PI3K/AKT PATHWAY INHIBITION IN PIK3CA-MUTANT HR+ BREAST CANCER

The MTB discussion centered on three major clinical trials establishing PI3K/AKT pathway targeting in PIK3CA-altered, endocrine-resistant HR-positive metastatic breast cancer:

SOLAR-1 (Alpelisib + Fulvestrant): Phase III trial (BYL719 with fulvestrant) demonstrated significant progression-free survival benefit with alpelisib (PI3Kα-selective inhibitor) plus fulvestrant versus placebo plus fulvestrant in PIK3CA-mutant, HR+/HER2- advanced breast cancer following progression on aromatase inhibitor-based therapy. In the PIK3CA-mutant cohort (n=341), median PFS was 11.0 months versus 5.7 months (HR 0.65, 95% CI 0.50–0.85, $p<0.001$). The E545K mutation detected in this patient is specifically listed among FDA-approved actionable PIK3CA alterations. However, alpelisib carries significant risk of hyperglycemia (grade 3-4 in 36.6% of patients), requiring intensive glucose monitoring—particularly problematic in this diabetic patient (18).

CAPItello-291 (Capivasertib + Fulvestrant): Phase III trial of capivasertib (AKT inhibitor) plus fulvestrant versus placebo plus fulvestrant in endocrine-resistant HR+/HER2- advanced breast cancer after 1-2 prior lines of therapy. In the AKT pathway-altered subgroup (PIK3CA/AKT1/PTEN alterations, n=289), median PFS was 7.3 months versus 3.1 months (HR 0.50, 95% CI 0.38–0.65, $p<0.001$). FDA approval was granted in November 2023 for tumors with PIK3CA, AKT1, or PTEN alterations. Capivasertib represents a downstream AKT-targeted approach with potentially broader pathway coverage than PI3K-selective inhibitors and importantly demonstrates lower rates of severe hyperglycemia (5.9% grade 3-4) compared to alpelisib (19).

INAVO120 (Inavolisib + Palbociclib + Fulvestrant): Recent FDA approval (December 2024) for inavolisib (GDC-0077, oral PI3Kα inhibitor) in combination with palbociclib and fulvestrant for PIK3CA-mutant, endocrine-resistant HR+/HER2- locally advanced or metastatic breast cancer. The trial demonstrated median PFS of 15.0 months versus 7.3 months with placebo combination (HR 0.43, p<0.0001). This represents a novel triple-combination approach integrating PI3K inhibition with concurrent CDK4/6 blockade, though real-world access and cost remain limiting factors in Indian practice (20).

2) Benefit of Switch-Hit treatment strategies beyond prior CDK4/6 inhibitors progression

In HR+/HER2- metastatic breast cancer, continuing the same CDK4/6 inhibitor beyond progression has generally not translated into meaningful PFS or OS gains. In the randomized PACE study, maintaining palbociclib with a switch to fulvestrant after prior CDK4/6i + AI progression did not improve PFS compared with fulvestrant alone, and no overall survival advantage emerged. Similarly, PALMIRA failed to demonstrate a significant PFS benefit with palbociclib rechallenge, reinforcing that simple continuation of the same agent is unlikely to overcome acquired resistance.

In contrast, switching to a different CDK4/6 inhibitor appears biologically and clinically more rational. Preclinical data suggests incomplete cross-resistance among CDK4/6 inhibitors due to pharmacologic differences (e.g., abemaciclib's broader CDK inhibition profile and continuous dosing). The phase II MAINTAIN trial showed that switching endocrine therapy and introducing ribociclib after prior CDK4/6i improved PFS versus endocrine therapy alone. More robustly, the phase III postMONARCH trial demonstrated a statistically significant PFS benefit with abemaciclib + fulvestrant after progression on prior CDK4/6i + ET. While OS data remain maturing, these findings support a "switch-hit" strategy—changing both the endocrine partner and the CDK4/6 inhibitor—rather than persisting with the same molecule beyond resistance. (35).

3) PARP Inhibitors in BRCA-Mutated Breast Cancer

Germline BRCA mutations (established indication): The OlympiAD trial established olaparib monotherapy for germline BRCA1/2-mutated HER2- metastatic breast cancer previously treated with chemotherapy, demonstrating median PFS of 7.0 months versus 4.2 months with chemotherapy (HR 0.58, p<0.001). Similarly, the EMBRACA trial demonstrated talazoparib superiority over chemotherapy (median PFS 8.6 vs 5.6 months, HR 0.54, p<0.001) (21,22). Both trials required germline BRCA mutations and excluded patients with somatic-only alterations.
Somatic BRCA mutations (limited evidence): NCCN guidelines list PARP inhibitors as Category 2B (lower level of consensus) for somatic BRCA mutations in breast cancer. Evidence is largely extrapolated from germline data; prospective validation lacking. Critically, low-VAF somatic mutations (<10% VAF) have not been specifically studied in any prospective trial, and platinum-refractory disease was generally an exclusion criterion or associated with poor PARP inhibitor response in exploratory analyses (23).

Circulating Tumor DNA (ctDNA) - Dynamic Clonal Cartography

In advanced HR+/HER2- breast cancer, ctDNA is most valuable because it can reveal molecular progression and resistance months–weeks before radiologic progression, and it provides an objective readout of treatment efficacy (falling/clearing ctDNA) while the patient

is still "clinically stable." In metastatic disease, serial ctDNA quantification tracks tumor burden and response more dynamically than conventional markers and often changes earlier than scans; the landmark NEJM study showed ctDNA closely mirrored treatment response and rising ctDNA anticipated progression compared with CA15-3/CTCs. In HR+/HER2- patients specifically treated with CDK4/6i-based therapy, longitudinal ctDNA rise commonly preceded radiologic PD with a median lead time ~83 days (range 14–309 days) in one cohort.

The strongest "practice-changing" evidence is that ctDNA isn't just prognostic—it can trigger an earlier, more effective treatment switch. PADA-1 (phase III) proved that detecting emergent/rising ESR1 mutations in ctDNA and switching from AI to fulvestrant while continuing palbociclib improved outcomes versus waiting for imaging-defined progression. SERENA-6 (phase III) extended this concept globally: ctDNA detection of emergent ESR1 followed by an early endocrine switch to camizestrant + ongoing CDK4/6i significantly prolonged PFS (reported HR ~0.44; median PFS 16.0 vs 9.2 months).

Beyond resistance interception, early ctDNA dynamics after therapy start can function like a rapid "on-treatment efficacy test," where early ctDNA decline/clearance predicts longer control and can rationalize earlier pivoting away from ineffective therapy. (25-30)

THERAPEUTIC CONSIDERATIONS

PATHWAY PRIORITIZATION LOGIC

PRIORITIZING MOLECULAR ALTERATIONS IN METASTATIC HR+/HER2- BREAST CANCER

Domain	Genomic Finding	What Genomics Suggests	Guideline Position (NCCN / ESMO)	Clinical Interpretation	Teaching Pearl
PIK3CA mutation	PIK3CA p. E5 45K • Hotspot mutation • VAF ~37%	• Constitutive PI3K/AKT activation • Endocrine resistance	• Category 1 recommendation • Alpelisib + Fulvestrant • Capivasertib + Fulvestrant (post-CDK4/6)	• High-VAF clonal driver • Concordant endocrine-resistant phenotype	High-VAF + phenotype + RCT evidence = prioritize
BRCA2 alteration	BRCA2 truncating variant • Somatic • Low VAF ~5%	• Possible HRD • Potential PARP sensitivity	• Category 1 only for germline BRCA • Somatic BRCA = Category 2B	• Platinum-refractory disease argues against functional HRD	Pathogenic ≠ dominant ≠ actionable
Variant Allelic Fraction	High vs Low VAF	• Estimates clonal dominance	• Not explicitly incorporated	• Strong predictor of therapeutic dependency	VAF bridges genomics and biology
Platinum response	PFS ~4 months	• Weak HRD signal	• Platinum sensitivity recognized as HRD surrogate	• Rapid relapse overrides isolated genomic HR signals	Clinical behavior trumps NGS
PARP1 amplification	Copy number gain	• Possible DDR pathway relevance	• No guideline-supported indication	• Likely compensatory / resistance mechanism	Modifiers explain behavior, not targets
TP53 mutation	TP53 nonsense • High VAF	• Aggressive biology	• Not directly targetable	• Explains rapid progression and resistance	Contextual mutation, not a target

The MTB applied a systematic framework for prioritizing competing molecular signals:

- Allelic fraction as proxy for clonal dominance: High-VAF mutations (PIK3CA 37%) represent dominant drivers present in most tumor cells; low-VAF mutations (BRCA2 5%) may be sub clonal, acquired late, or functionally irrelevant.
- Clinical phenotype as functional validation: Platinum resistance (4-month PFS) argues against HRD dominance despite BRCA2 alteration. Functional HRD typically manifests as prolonged platinum sensitivity (median 7-12 months).
- Evidence strength hierarchy: Level 1 evidence (randomized Phase III trials) favoring PI3K/AKT inhibition (SOLAR-1, CAPItello-291) versus extrapolated evidence for low-VAF somatic BRCA2 (no prospective data).
- Toxicity and accessibility: Capivasertib available in India with manageable toxicity profile; alpelisib carries significant hyperglycemia risk (problematic in diabetic patient); PARP inhibitors lack clear indication given low VAF and platinum resistance.
- Sequential strategy preservation: Target dominant pathway first (PI3K/AKT); reserve PARP inhibitors for progression only if HRD reassessment shows higher BRCA2 VAF, germline mutation confirmed, or platinum re-challenge demonstrates response.

KEY LEARNING POINTS

1. Variant allelic fraction (VAF) matters: High-VAF mutations (PIK3CA 37%, TP53 32%) represent clonal drivers present in the founding tumor population and typically predict therapeutic response more reliably than low-VAF alterations (BRCA2 5%), which may be sub clonal, late-acquired, or functionally irrelevant.
2. Clinical phenotype validates molecular findings: Platinum resistance (4-month PFS) despite BRCA2 mutation indicates the alteration is not functionally dominant for homologous recombination deficiency. Treatment response patterns provide critical functional validation that genomic data alone cannot establish.
3. PI3K/AKT pathway inhibition has Level 1 evidence in PIK3CA-mutant disease: Capivasertib (CAPItello-291) and alpelisib (SOLAR-1) demonstrated significant PFS benefit in PIK3CA-mutant, endocrine-resistant HR+ breast cancer, establishing these as evidence-based standard options.
4. PARP inhibitors require careful patient selection: Somatic BRCA mutations—particularly low-VAF alterations (<10%)—in platinum-resistant disease do not automatically warrant PARP inhibition. Evidence is strongest for germline BRCA mutations with platinum sensitivity.
5. Treatment history informs pathway prioritization: Sequential CDK4/6 resistance (24+ months through two platforms) followed by rapid chemotherapy relapses define aggressive, adaptable biology with multiple bypass mechanisms, supporting multi-modal targeting strategies.
6. Resource context matters in precision oncology: Drug availability, toxicity profile (hyperglycemia risk in diabetic patient), monitoring capacity (intensive glucose checks), and out-of-pocket cost influence real-world recommendations—precision oncology must account for practical implementation feasibility.
7. Sequential single-agent targeting preserves options: Target dominant pathway first (PI3K/AKT) while disease biology is defined; reserve alternative mechanisms (PARP inhibition) for progression when molecular reassessment can guide selection, avoiding premature combination strategies without evidence base.
8. Clonal dominance predicts therapeutic dependency: Genomic alterations with high VAF and mechanistic alignment with clinical phenotype (PIK3CA mutation explaining endocrine resistance) represent actionable drivers; low-VAF alterations require clinical validation before informing treatment selection.

FINAL RECOMMENDATION (MTB CONSENSUS)

Primary Recommendation:

Capivasertib 400 mg orally twice daily (4 days on, 3 days off schedule) plus Fulvestrant 500 mg intramuscularly (Days 1, 15, 29, then monthly), targeting the dominant PI3K/AKT pathway driver in endocrine-resistant, PIK3CA-mutant HR+ metastatic breast cancer.

Rationale

- High-VAF PIK3CA mutation (37%) represents clonal driver with Level 1 evidence supporting AKT inhibition (CAPItello-291 trial).
- Capivasertib + fulvestrant demonstrated superior PFS in PIK3CA-altered cohort (median 7.3 vs 3.1 months, HR 0.50).
- Better tolerated than alpelisib in diabetic patient—lower incidence of severe hyperglycemia (5.9% vs 36.6% grade 3-4).
- Available in Indian market (branded and generic formulations) with manageable toxicity profile requiring standard supportive care.
- Low-VAF BRCA2 (5%) with platinum-refractory phenotype argues against PARP inhibitor as primary strategy; defer pending germline testing and HRD reassessment.

Alternative Options (if capivasertib unavailable)

- Alpelisib 300 mg orally once daily + fulvestrant 500 mg IM (SOLAR-1 regimen): Requires intensive glucose monitoring with endocrinology co-management for diabetes optimization.
- Everolimus 10 mg orally once daily + exemestane 25 mg orally once daily: mTOR inhibitor alternative with older evidence base (BOLERO-2 trial, 2012); lower cost but less specific targeting than PI3K/AKT inhibitors.

Deferred/Future Considerations

- Germline BRCA testing: Recommend germline genetic testing to distinguish inherited (germline) versus acquired (somatic-only) BRCA2 mutation status. Germline status may inform family counseling and potentially alter PARP inhibitor indication.
- Repeat molecular profiling at progression: Consider repeat NGS from metastatic site biopsy or liquid biopsy (ctDNA) including HRD genomic signature assessment, BRCA2 VAF reassessment, and evaluation for acquired resistance mechanisms (ESR1 mutations, PTEN loss).
- PARP inhibitor consideration: Reserve for future line only if (a) germline BRCA2 confirmed, (b) HRD signature documented with higher BRCA2 VAF, or (c) platinum re-challenge demonstrates durable response (>6 months PFS).
- Clinical trial enrollment: Explore eligibility for novel PI3K/AKT/mTOR pathway inhibitors, next-generation AKT inhibitors, or rational combination trials (e.g., AKT inhibitor + immune checkpoint inhibitor).

References

1. *Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22(1):45. doi: 10.1186/s13058-020-01284-9*
2. *André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-40. doi: 10.1056/NEJMoa1813904*
3. *Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-33. doi: 10.1056/NEJMoa1706450*
4. *Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-63. doi: 10.1056/NEJMoa1802905*
5. *Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12(4):1157-67. doi: 10.1158/1078-0432.CCR-05-1029*
6. *Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res. 2014;20(13):3569-80. doi: 10.1158/1078-0432.CCR-13-2943*
7. *Quan C, Wu Z, Xiong J, Li M, Fu Y, Su J, et al. Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation. Exp Hematol Oncol. 2023;12(1):100. doi: 10.1186/s40164-023-00462-7*
8. *Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, et al. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol. 2012;23(5):1156-64. doi: 10.1093/annonc/mdr361*
9. *Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-36. doi: 10.1056/NEJMoa1607303*
10. *Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-39. doi: 10.1016/S1470-2045(15)00613-0*
11. *Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394-405. doi: 10.1056/NEJMoa2105215*
12. *Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660*
13. *Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477*
14. *Den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017;161(3):549-56. doi: 10.1007/s10549-016-4080-9*

15. *Dogruluk T, Tsang YH, Espitia M, Chen F, Chen T, Chong Z, et al. Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. Cancer Res. 2015;75(24):5341-54. doi: 10.1158/0008-5472.CAN-15-1654*
16. *Leontiadou H, Galdadas I, Athanasiou C, Cournia Z. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations. Sci Rep. 2018;8(1):15544. doi: 10.1038/s41598-018-27044-6*
17. *Tung N, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38(36):4274-82. doi: 10.1200/JCO.20.02151*
18. *André F, Ciruelos E, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32(2):208-17. doi: 10.1016/j.annonc.2020.11.011*
19. *Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-70. doi: 10.1056/NEJMoa2214131*
20. *Juric D, Kalinsky K, Oliveira M, Cervantes A, Bedard PL, Bianchini G, et al. Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer (INAVO120): a randomised, phase 3 trial. Lancet Oncol. 2024;25(9):1203-14. https://doi.org/10.1158/1538-7445.SABCS23-GS03-13*
21. *Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558-66. doi: 10.1093/annonc/mdz012*
22. *Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526-35. doi: 10.1016/j.annonc.2020.08.2098*
23. *National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2025 [Internet]. Plymouth Meeting (PA): NCCN; 2024 [cited 2025 Jan 31]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.*
24. *Chiu J, Su F, Joshi M, Masuda N, Ishikawa T, Aruga T, Zarate JP, Babbar N, Balbin OA, Yap YS. Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial. BMC Med. 2023 Aug 15;21(1):306. doi: 10.1186/s12916-023-03017-z.*
25. *Mamann A, Pradat Y, Bidard FC, Delaloge S, Cabel L, Faull I, Marques S, Bachelot T, Dalenc F, de la Motte Rouge T, Pistilli B, Samaniego J, Frenel JS, Levy C, Ferrero JM, Sabatier R, Ladoire S, Chakiba C, Hardy AC, Lemonnier J, Mahi Y, Andre F, Cournede PH, Michiels S, Bernard E. Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer. Ann Oncol. 2025 Nov;36(11):1342-1355. doi: 10.1016/j.annonc.2025.06.015.*
26. *Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013 Mar 28;368(13):1199-209. doi: 10.1056/NEJMoa1213261.*

27. *Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1.*
28. *Pontolillo L, Davis AA, Gerratana L, Medford AJ, Wang J, Nicolo' E, Clifton K, Velimirovic M, Warrior S, Podany E, Andreopoulou E, Serafini MS, Munoz-Arcos L, Molteni E, Lipsyc-Sharf M, Gianni C, Bayou N, Dai CS, Giannarelli D, Bria E, Ma CX, Bardia A, Reduzzi C, Cristofanilli M. Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis. NPJ Breast Cancer. 2025 Aug 16;11(1):93. doi: 10.1038/s41523-025-00802-2.*
29. *Taranto E, DeMichele A. Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression - lessons from SERENA-6. NPJ Breast Cancer. 2026 Jan 29;12(1):18. doi: 10.1038/s41523-026-00894-4.*
30. *Medford AJ, Wander SA. SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine. Nat Rev Clin Oncol. 2025 Nov;22(11):804-805. doi: 10.1038/s41571-025-01066-2.*
31. *Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, Nag S, da Silva EM, Yildirim SY, Li Q, O'Connell E, Patel P, Will M, Fushimi A, Benitez M, Bradic M, Fan L, Nakshatri H, Sudhan DR, Denz CR, Reis-Filho JS, Goel S, Koff A, Weigelt B, Khan QJ, Razavi P, Chandarlapaty S. Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell. 2024 Nov 11;42(11):1983. doi: 10.1016/j.ccell.2024.10.013. Erratum for: Cancer Cell. 2024 Nov 11;42(11):1919-1935.e9. doi: 10.1016/j.ccell.2024.09.009. PMID: 39532066.*
32. *Aylon Y, Furth N, Pirona AC, Lavie A, Fedorova O, Hassin O, Padrão N, Steinmetz M, Sarusi-Potuguez A, Fellus-Alyagor L, Shimoni I, Dassa B, Zwart W, Shema E, Oren M. p53 regulates the expression of histone modifiers to restrict stemness and maintain differentiated luminal identity in breast cancer. Proc Natl Acad Sci U S A. 2025 Nov 4;122(44):e2522646122. doi: 10.1073/pnas.2522646122. Epub 2025 Oct 29.*
33. *Ji JH, Bae SJ, Kim K, Chu C, Lee KA, Kim Y, Kim JH, Jeong J, Ahn SG. Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer. NPJ Breast Cancer. 2022 Feb 16;8(1):19. doi: 10.1038/s41523-022-00384-3.*
34. *Shahbandi A, Nguyen HD, Jackson JG. TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. Trends Cancer. 2020 Feb;6(2):98-110. doi: 10.1016/j.trecan.2020.01.007.*
35. *Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-49. doi: 10.1016/j.annonc.2020.09.010*
36. *ESMO Guidelines Committee. Breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [Internet]. Geneva: ESMO; 2023 [cited 2025 Jan 31]. Available from: https://www.esmo.org/guidelines/breast-cancer*
37. *Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475-95. doi: 10.1016/j.annonc.2021.09.019*